Clinton Snow
Direktor/Vorstandsmitglied bei ICETANA LIMITED
Aktive Positionen von Clinton Snow
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ICETANA LIMITED | Direktor/Vorstandsmitglied | 08.02.2022 | - |
DIMERIX LIMITED | Direktor/Vorstandsmitglied | 01.05.2023 | - |
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Direktor/Vorstandsmitglied | - | - |
Karriereverlauf von Clinton Snow
Ausbildung von Clinton Snow
University of Melbourne | Undergraduate Degree |
Statistik
International
Australien | 5 |
Operativ
Director/Board Member | 3 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 3 |
Technology Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ICETANA LIMITED | Technology Services |
DIMERIX LIMITED | Health Technology |
Private Unternehmen | 1 |
---|---|
PolyActiva Pty Ltd.
PolyActiva Pty Ltd. BiotechnologyHealth Technology PolyActiva Pty Ltd. develops drug-polymer conjugate technology. Its platform technology is used to make plastic components for medical devices from drugs and manufacture process is novel and provides greater flexibility over the composition of the final material and better product outcomes compared with competitor technologies. The firm has built drug-polymer conjugates from a number of drug candidates with different chemical structures and linkage points, demonstrating the plasticity of the technology and developed a number of functional co-monomers and polymer segments, which modularises the production of the final conjugate. The company was founded in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
- Börse
- Insiders
- Clinton Snow
- Erfahrung